Urszula Wojtyra is a partner in Smart & Biggar's Toronto office. Her practice focusses on life sciences (pharmaceuticals, biologics, medical devices, natural health products).
Urszula has represented clients before both the Federal Court and the Federal Court of Appeal of Canada, and regularly represents innovative pharmaceutical and biopharmaceutical companies in complex patent litigation, including patent infringement actions and proceedings under the Patented Medicines (Notice of Compliance) Regulations. Her extensive experience and skills in strategic litigation management makes Urszula a valued and key member of Smart & Biggar's litigation team. Most recently, Urszula was a member of the team that successfully represented AstraZeneca in its patent infringement action against Apotex, including in the recovery of Apotex's profits: AstraZeneca Canada Inc. v. Apotex Inc., 2015 FC 322 and 2017 FC 726 (LOSEC, omeprazole).
Urszula also advises clients on regulatory due diligence, regulatory compliance issues (under the Food and Drugs Act and associated regulations) and has broad expertise in regulatory matters in Canada, including related to biologics.
Prior to attending law school, Urszula obtained her Master of Science in biochemistry from the University of Toronto and worked in an immunology research laboratory in Toronto's Hospital for Sick Children. Her technical expertise in biochemistry, chemistry, molecular biology, immunology, genetics, and medicine further empowers Urszula to successfully advise and represent her clients.
She is a regular contributor to Rx IP Update, Smart & Biggar's monthly pharmaceutical and biopharmaceutical intellectual property and regulatory newsletter.
Urszula is past Chair of the IPIC Competition Law Committee; an associate of the Intellectual Property Institute of Canada; and a member of the Women in IP Network, the Toronto Intellectual Property Group and The Advocates' Society.
Since 2015, Urszula has been recognized as a 'Rising Star' under Life Sciences.